Is there an association between alpha 2-Heremans-Schmid glycoprotein (AHSG) gene Thr256Ser polymorphisms with aortic calcification in regular hemodialysis patients in Medan, Indonesia
Aim Alpha2-Heremans-Schmid glycoprotein (AHSG), a circulating plasma protein, plays an essential role in bone and vascular mineralization. The impact of AHSG gene polymorphisms on aortic calcification in haemodialysis patients was inconsistent. We performed this study to clarify precise association among AHSG gene Thr256Ser single-nucleotide polymorphisms and aortic calcification. Methods Patients on stable regular haemodialysis treatment for more than thirty months were included in a cross-sectional study at Rasyida Renal Hospital Medan. Lateral spine X-rays were performed to evaluate the aortic calcification. Genotyping for the polymorphisms was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) techniques. Results Aortic calcification was detected in 69.8% of patients. From 106 patients, 49 patients (46.2 %) had CC (Thr/Thr), 54 (51.0%) had CG (Thr/Ser) and three (2.8%) patients had GG (Ser/ Ser) polymorphism. The proportion of patients with heterozygous or homozygous G allele (CG and GG genotypes) is more likely (91.2%) to have aortic calcification. The bivariate analysis showed that Thr256Ser polymorphism (G allele) was associated with increased risk for aortic calcification (PR = 2.03; 95% CI 1.48-2.80; p<0.001). However, overall results from multivariate analysis showed that Fetuin-A level <204 pg/mL (PR = 22.0; 95% CI 3.32-145.91; p=0.001) and IL-6 level ≥53.05 mg/dL (PR = 19.50; 95% CI 2.87-132.41; p=0.002) were the major risk factors for the occurrence of aortic calcification. Conclusion AHSG Thr256Ser gene polymorphism showed an association with aortic calcification in regular haemodialysis patients, but Fetuin-A and IL-6 have a dominant role in the development of aortic calcification.
Neven E, Haese P. Vascular calcification in chronic renal failure what have we learned from animal studies? Circ Res. 2011. p. 249–64.
3.
Maharem D, Gomaa S, El-Ghandor M, Matrawy M, Zaytoun K, Nomeir S, et al. Association of serum fetuin-A and fetuin-A gene polymorphism with mineral and bone disorders in patients with chronic kidney disease. Egypt J Med Hum Genet. 2013. p. 337–52.
4.
Mann A, Makkar V, Mann S, Dhamija P, Soundarajan P. Fetuin-A, and vascular calcification in Indian end-stage renal disease population. Indian J Nephrol. 2017. p. 33–8.
5.
Fiore C, Celotta G, Politi G, Di P, Castelli Z, Mangiafico R, et al. Association of high alpha 2 -Heremans -Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. J Atherosclerosis. 2007. p. 110–5.
6.
Zeidan M, Sharara G, Suliman H, Zeid M, Zytoun S, Nomeir H. Visfatin and Fetuin-A: novel markers for endothelial dysfunction in chronic kidney disease. Life Sci J. 2012. p. 227–43.
7.
Yong J, Hwang Y, Lee H, Lee H. Association of AHSG gene polymorphisms and aortic stiffness in peritoneal dialysis. Am J Nephrol. 2010. p. 510–7.
8.
Stenvinkel P, Wang K, Qureshi A, Axelsson J, Pecoits-Filho R, Gao P, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005. p. 2383–92.
9.
Raggi P, Bellas A, Ferramosca E, Islam T, Muntner P, Block G. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int. 2007. p. 802–7.
10.
Hashimoto H, Iijima K, Hashimoto H, Son B, Ota H, Ogawa S, et al. Validity and usefulness of aortic arch calcification in chest Xray. J Atheroscler Thromb. 2008. p. 256–64.
11.
Honkanen E, Kauppila L, Wikstrom B, Rensma P, Krzesinski J, Aasarod K, et al. CORD study group. Abdominal aortic calcification in dialysis patients: results of the CORD study. Nephrol Dial Transplant. 2008. p. 4009–15.
12.
Kazancioglur. Risk factors for chronic kidney disease: an update. Kidney Int. 2013. p. 368–71.
13.
Lumlertgul D, Kantachuvesiri S, Apichaiyingyurd S, Treamtrakanpon W, Rattanasompattikulm, Gojaseni P, et al. Impact-CKD investigators. Prevalence of and predictive factor for abdominal aortic calcification in Thai chronic kidney disease patients. Ther Apher Dial. 2017. p. 611–9.
14.
Nkf Kdoqi Guidelines. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. 2013.
15.
El-Shehaby A, Zakaria A, El-Khatib M. Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest. 2010. p. 575–82.
16.
Alwahaibi N, Alissaei H, Al-Kabbani A, Alabi N, Allawati Z. Evaluation of kidney diseases and transplantation original article evaluation of interleukin-2, interleukin-8, and tumor necrosis factor-like weak inducer of apoptosis in hemodialysis and renal transplant patients and healthy controls. Saudi J Kidney Dis Transpl. 2016. p. 1123–8.
17.
Altuntaş A, Yiğit A, Uz E, İnal S, Kadir V, Basri H. The relationship between serum fetuin a levels and fetuin gene polymorphism in hemodialysis patients. Biomed Res. 2017. p. 495–502.
18.
Rosa-Diez G, Italiano H, Aires D, Laham G, Italiano H, Aires D. Prevalence of factors related to vascular calcification in patients with chronic kidney disease on dialysis. Medicina (B Aires). 2017. p. 207–13.
19.
Jayalath R, Mangan S, Golledge J. Aortic calcification. Eur J Vasc Endovasc Surg. 2005. p. 476–88.
20.
Kuzniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end-stage kidney disease. J Ren Nutr. 2008. p. 83–6.
21.
Wang A, Woo J, Lam C, Wang M, Chan I, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis, and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005. p. 1676–85.
22.
Ziyrek M, Tayyareci Y, Yurdakul S, Aytekin S. Association of mitral annular calcification with endothelial dysfunction, carotid intima-media thickness, and serum fetuin-A: an observational study. Anadolu Kardiyol Derg. 2013. p. 752–8.
23.
Leopold J. Vascular calcification: mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med. 2015. p. 267–74.
24.
Heiss JDW, Scha A, Ketteler C, M. Fetuin-A regulation of calcified matrix metabolism. Circ Res. 2011. p. 1494–509.
25.
Joachim H, Chertow G, Shlipak M, Brandenburg V, Ketteler M, Whooley M. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation. 2007. p. 2533–9.
26.
Zheng S, Fuentes L, Blerhals A, Bernal R, Spence K, Slatopolsky E, et al. Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis. Am J Cardiol. 2009. p. 46–9.
27.
Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of alpha2-HS glycoprotein (AHSG, Fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet. 2005. p. 146–51.
28.
Henaut L, Massy Z. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. Nephrol Dial Transplant. 2018. p. 543–8.
29.
Kaminska J, Stopinski M, Muchak, Jędrzejczak A, Gołębiowski M, Niewczas M, et al. Foroncewicz B. IL 6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. Cytokine. 2019. p. 9–14.
30.
Oikawa O, Higuchi T, Yamazaki T. Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007. p. 304–8.
31.
Yamada S, Tokumoto M, Tsuruya K, Tatsumoto N, Noguchi H, Kitazono T, et al. Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. Am J Physiol Renal Physiol. 2015. p. 744–54.
32.
Choi S, Lee Y, Cho A, Park H, Han C, Choi M, et al. Malnutrition, inflammation, the progression of vascular calcification and survival: Interrelationships in hemodialysis patients. PloS One. 2019. p. 1–14.
33.
Arad Y, Goodman K, Roth M, Newstein D, Guerci A. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events. J Am Cool Cardiol. 2005. p. 158–65.
34.
Russo D, Imbriaco M, Pota A, Russo L, Scognamiglio B, Sorrentino R. Coronary artery calcification and outcomes in diabetic patients with and without chronic kidney disease. World J Cardiol. 2013. p. 17–20.
35.
Wang N, Yang J, Yu X, Hu J, Xing C, Ju X, et al. Radial artery calcification in end-stage renal disease patients is associated with deposition of osteopontin and diminished expression of alpha-smooth muscle actin. Nephrology (Carlton). 2008. p. 367–75.
36.
Shanahan C, Crouthamel M, Kapustin A, Giachelli C. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011. p. 697–711.
37.
Toussaint N, Lau K, Strauss B, Polkinghorne K, Kerr P. Associations between vascular calcification, arterial stiffness, and bone mineral density in chronic kidney disease. Nephrol Dial Transplant. 2008. p. 586–93.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
